COMMUNIQUÉS West-GlobeNewswire

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
21/09/2024
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia throu gh scientific and clinical advances that support optimal treatment options and decisions for [...]
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
21/09/2024
Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant Approval based on positive [...]
Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué (...)
21/09/2024
Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué, non éligibles à une [...]
Smart for Life Provides Update Following Nasdaq Delisting Due to Audit Delays; Reports Plans to Reapply to Nasdaq Upon Full Compliance
20/09/2024
MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (OTC: SMFL) (“Smart for Life” or the “Company”), a distinguished leader in the Health & Wellness sector specializing in the marketing and manufacturing [...]
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20/09/2024
BRISBANE, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class 1 targeted and immune-mediated therapeutics to fight [...]
Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024
20/09/2024
JI’AN, Jiangxi, China, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company,” “we,” “our” and “us”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced its [...]
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20/09/2024
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody-drug [...]
ONWARD® Medical Annonce la Cotation de ses Titres sur le Marché Euronext Paris
20/09/2024
La société a des racines françaises et des liens significatifs avec la France La société collabore étroitement avec le CEA-Clinatec, institut de recherche biomédicale de renommée mondiale financé par le gouvernement [...]
L’Arche Vancouver opens new $37-Million Dream Home
20/09/2024
BURNABY, British Columbia, Sept. 20, 2024 (GLOBE NEWSWIRE) -- L’Arche Greater Vancouver has fulfilled the biggest dream in its 50-year history today, by replacing its old building on the Sussex Avenue property in [...]
Wounded Warriors Family Support Provides Veterans with Program Toward Financial Competency, Independence
20/09/2024
OMAHA, Neb., Sept. 20, 2024 (GLOBE NEWSWIRE) -- According to a 2021 Military Family Support Programming Survey, 80.7% of respondents indicated that their finances caused them some stress over the past 12 months. The [...]
Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C
20/09/2024
MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disease MIPLYFFA is indicated for use in combination with miglustat for the treatment [...]
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.
20/09/2024
TAMPA, FL and COMMACK, NY, Sept. 20, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. (“TRxADE”) (NASDAQ: MEDS) and Scienture, LLC (“Scienture”), a wholly owned subsidiary of TRxADE, today announced that it is changing its [...]
Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders
20/09/2024
CINCINNATI, Ohio, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of [...]
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs
20/09/2024
PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group " or the [...]
ChemoMetec makes offer to buy Ovizio Imaging Systems SA
20/09/2024
ANNOUNCEMENT NO. 276 20 September 2024 ChemoMetec makes offer to buy Ovizio Imaging Systems SA ChemoMetec has submitted an indicative offer to buy Belgian company Ovizio Imaging Systems (‘Ovizio’), which has been [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
20/09/2024
Please see enclosed pdf. Attachment 20092024_trading_in_shares_LRA
Range Impact Announces Application to Uplist to the OTCQB Venture Market
20/09/2024
CLEVELAND, OHIO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public company dedicated to improving the health and wellness of people and the planet through a [...]
Koelis Announces Partnership and Initial Experience with DeepHealth for AI-powered Prostate MRI Interpretation and Guidance in Fusion Biopsy
20/09/2024
GRENOBLE, France and PRINCETON, N.J., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com ), a global leader and innovator in prostate care, announced today the partnership and [...]
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
20/09/2024
Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic [...]

Pages